Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-analysis

Conclusion: The addition of EGFR-mAbs to gemcitabine-based first-line CHT does not significantly improve overall and progression-free survival, nor the objective response rate in patients with advanced BTC and increases the risk of hematological and cutaneous adverse drug events.

Source: In Vivo - February 27, 2020 Category: Research Authors: RIZZO, A., FREGA, G., RICCI, A. D., PALLONI, A., ABBATI, F., DE LORENZO, S., DESERTI, M., TAVOLARI, S., BRANDI, G. Tags: Review Source Type: research